CPIC 2026 | Computing Power × Human Endeavor × R&D Capability: New Paradigm of Innovative Drug R&D in the AI Era Session Agenda Released
Update time:
2026-05-30 10:31
Reads:
Over the past two years, AI has emerged as one of the most closely watched factors in pharmaceutical R&D. However, for the innovative drug industry, the core question has never been whether AI can generate content. Instead, it lies in whether AI can integrate into real-world R&D workflows, support scientific decision-making, deliver quality-assured outputs, and gain genuine trust and adoption within heavily regulated, high-liability, and highly collaborative working environments.
On the afternoon of July 22, the session Computing Power ×Human Endeavor ×R&D Capability:New Paradigm of Innovative Drug R&D in the AI Era, co-hosted by Foxu.AI, Jeyou Pharma and the Shanghai Institute for Clinical Innovation & Translation, will take place during CPIC 2026.
This session will feature in-depth discussions covering key topics: AI medical technology evolving from technical concepts to clinical applications, the re-evolution of innovative drug R&D organizations in the AI era, the In Silico Workforce within highly regulated R&D environments, and the launch of industrialized trusted knowledge delivery scenarios built on Hospital GCP, Biotech, CRO and Foxu.AI.
Session Agenda
Co-host: Foxu.AI、Jeyou Pharma、Shanghai Academy of Clinical Innovation and Translational Science
AI Medical Technology: From Technical Concepts to Clinical Application
Qingsong Qin, Shanghai Institute for Clinical Innovation & Translation
Computing Power × Human Endeavor: Re-evolution of Innovative Drug R&D Organizations in the AI Era
Jianfeng Peng, Professor of Renmin University of China; Chairman, China Stone
In Silico Workforce in Highly Regulated R&D Scenarios: From Report Generation to Process Quality Control
Hongming Liang, Co-founder & Chief Scientist, Foxu.AI
Hospital GCP × Biotech × CRO × Foxu.AI: Launch of Industrialized Scenarios for Trusted Knowledge Delivery
How Will AI Reshape the Relationship Between Pharma Companies and CRO/CMO in the Next Three Years?
Tong Guo, CEO of Clinical Research Center,GoBroad Healthcare Group
Bingshi Guo, General Manager of Macromolecule R&D Platform, Jeyou Pharma
Hui Zhou, Senior Vice President & Chief R&D Officer for Oncology Pipeline, Innovent Biologics
Lin Xia, Former Senior Reviewer of CDE; Deputy General Manager of TriApex Laboratories & CMO of TriApex (Nanjing)
Related News
Contact us
Address：Room 62, 6th Floor, Building 1, Zone 1, No.186 South 4th Ring West Road , Fengtai District, Beijing
Tel：010-83634390
Address：Address：Room 1704, Building E, Nanotechnology Park, SIP, Suzhou, Jiangsu Province
TONACEA
XIEYI Release
TONACEA Biotech
TONACEA Micro Service
